Abramson Cancer Center, University of Pennsylvania

The Abramson Cancer Center at the University of Pennsylvania in Philadelphia, NCI-designated as comprehensive, is where CAR-T became a drug through Carl H. June, Bruce L. Levine and the treatment of Emily Whitehead, where Karikó and Drew Weissman made mRNA druggable, recognised by the 2023 Nobel Prize, and where PARP PET was invented. Its record covers CTL019, now tisagenlecleucel, proved in ELIANA and JULIET, the in vivo CAR-T origins behind Capstan and Interius BioTherapeutics, 18F-FluorThanatrace PARP PET, proton therapy and the Basser Center for BRCA, with Robert H. Vonderheide and Robert H. Mach among its people. Nuclide links it to CAR-T for glioma, to the PROSE paper on preventive surgery in BRCA carriers, and to Children's Hospital of Philadelphia. Whether in vivo CAR-T can match ex vivo products is the question its spin-outs now test. Programmes are listed below.